Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial.
Qiuling ZhaoRuixiang XieWanfu ZhongWenbin LiuTing ChenXiuliang QiuLin Yang
Published in: Cost effectiveness and resource allocation : C/E (2023)
Adding durvalumab to gemcitabine and cisplatin was not cost-effective for advanced BTC regardless of receiving and not receiving charitable assistance.